[A case of long-term survival after undergoing S-1 based multidisciplinary therapy for liver metastasis of gastric cancer].
We encountered a case of gastric cancer accompanied with liver metastasis, which had a good response to chemotherapy of S-1. A 68-year-old female was admitted to our hospital due to further examination of gastric tumor detected by an outpatient physician. She was found to have a type-3 gastric cancer in upper gastrointestinal endoscopy and a metastatic tumor of the liver in abdominal CT. Although chemotherapy of S-1 was inducted for the lesions, both the primary and liver tumors were dramatically reduced. We subsequently performed total gastrectomy and partial hepatectomy. Abdominal CT scan at 11 months after the initial operation revealed metachronous liver metastasis. She received combination chemotherapy of S-1 and CDDP. After 5 courses of the combination chemotherapy, the liver tumor disappeared. She has survived for 8 years without a recurrence after the initial operation. There was negative findings of immunostaining with thymidylate synthetase (TS), which was target enzyme for 5-FU at a biopsy sample of the primary gastric tumor before chemotherapy of S-1. TS immunostaining may be a useful marker for S-1 combined therapy for gastric cancer associated with liver metastases.
Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
Gentaro
G
Ito
Naoshi
N
Kubo
Hiroaki
H
Tanaka
Kazuya
K
Muguruma
Katsunobu
K
Sakurai
Kenjiro
K
Kimura
Hisashi
H
Nagahara
Eiji
E
Noda
Ryosuke
R
Amano
Nobuya
N
Yamada
Masakazu
M
Yashiro
Kiyoshi
K
Maeda
Tetsuji
T
Sawada
Bunzo
B
Nakata
Masaichi
M
Ohira
Kosei
K
Hirakawa
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D020360:Neoadjuvant Therapy; D010094:Oxonic Acid / Q000627:therapeutic use*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid